U.S.
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site
Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations
BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs
BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns
Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles
Leqembi, Biogen, Eisai, Alzheimer’s disease, global sales, US adoption challenges
BIOSECURE Act: A Potential Game-Changer for Biopharma – Industry Implications and Future Directions
BIOSECURE Act, Biopharma industry, US-China relations, Biotechnology collaborations, Supply chain diversification, Regulatory compliance
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion
WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals
WuXi AppTec, BIOSECURE Act, US Deals, Pharmaceutical Manufacturing, Biotech Industry
Grünenthal Acquires US-Based Valinor Pharma for $250 Million
Grünenthal, Valinor Pharma, acquisition, Movantik, naloxegol, opioid-induced constipation, pain management, US market expansion, pharmaceutical industry
Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans
Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.